{Reference Type}: Journal Article
{Title}: Clinical characteristics of patients with bone sarcoidosis.
{Author}: Zhou Y;Lower EE;Li H;Farhey Y;Baughman RP;
{Journal}: Semin Arthritis Rheum
{Volume}: 47
{Issue}: 1
{Year}: 08 2017
{Factor}: 5.431
{DOI}: 10.1016/j.semarthrit.2017.02.004
{Abstract}: To assess the clinical features, diagnosis, and treatment of bone sarcoidosis in the United States.<BR>Patients with bone sarcoidosis were identified and matched to sarcoidosis patients based on race, gender, and age. Detailed characteristics were obtained by medical record review.<BR>A total of 64 patients with bone sarcoidosis were enrolled in this study. The female:male ratio was 1.46:1 and the white:black ratio was 3:1. Thirty-eight (59.4%) of 64 patients had bone symptoms. Compared to matched cases, bone sarcoidosis patients have more multi-organ involvement and higher incidence with liver, spleen, and extrathoracic lymph node involvement than controls (P < 0.05). Spine was the most commonly affected bone in 44 (68.8%) of patients, followed by pelvis (35.9%), and hands (15.6%). MRI and PET/CT scan was the common imaging technology, which performed in 36 patients and 32 patients, respectively, and with 97.2% and 93.8% positive bone uptake. Laboratory test indicated anemia was more common in bone sarcoidosis group than controls (P = 0.044). Infliximab was more commonly used in bone sarcoidosis patients than controls (P = 0.009).<BR>Bone sarcoidosis was associated with multi-organs affection, and high frequency of liver, spleen, or extrathoracic lymph node involvement. Infliximab should be considered in those patients with aggressive and refractory bone sarcoidosis.